Hypercalcitoninaemia in pseudohypoparathyroidism type 1A and type 1B

Maria P. Yavropoulou, Efstathios Chronopoulos, George Trovas, Emmanouil Avramidis, Francesca Marta Elli, Giovanna Mantovani, Pantelis Zebekakis, John G. Yovos

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Pseudohypoparathyroidism (PHP) is a heterogeneous group of rare endocrine disorders characterised by normal renal function and renal resistance to the action of the parathyroid hormone. Type 1A (PHP1A), which is the most common variant, also include developmental and skeletal defects named as Albright hereditary osteodystrophy (AHO). We present two cases, a 54- and a 33-year-old male diagnosed with PHP who were referred to us for persistently high levels of serum calcitonin. AHO and multinodular goitre were present in the 54-year-old male, while the second patient was free of skeletal deformities and his thyroid gland was of normal size and without nodular appearance. We performed GNAS molecular analysis (methylation status and copy number analysis by MS-MLPA) in genomic DNA samples for both patients. The analysis revealed a novel missense variant c.131T>G p.(Leu44Pro) affecting GNAS exon 1, in the patient with the clinical diagnosis of PHP1A. This amino acid change appears to be in accordance with the clinical diagnosis of the patient. The genomic DNA analysis of the second patient revealed the presence of the recurrent 3-kb deletion affecting the imprinting control region localised in the STX16 region associated with the loss of methylation (LOM) at the GNAS A/B differentially methylated region and consistent with the diagnosis of an autosomal dominant form of PHP type 1B (PHP1B). In conclusion, hypercalcitoninaemia may be encountered in PHP1A and PHP1B even in the absence of thyroid pathology.

Original languageEnglish
Article number18-0125
JournalEndocrinology, Diabetes and Metabolism Case Reports
Volume2019
Issue number1
DOIs
Publication statusPublished - Jan 1 2019

Fingerprint

Pseudohypoparathyroidism
Methylation
Thyroid Gland
Kidney
DNA
Goiter
Calcitonin
Parathyroid Hormone
Exons
Pathology
Amino Acids
Serum

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Yavropoulou, M. P., Chronopoulos, E., Trovas, G., Avramidis, E., Elli, F. M., Mantovani, G., ... Yovos, J. G. (2019). Hypercalcitoninaemia in pseudohypoparathyroidism type 1A and type 1B. Endocrinology, Diabetes and Metabolism Case Reports, 2019(1), [18-0125]. https://doi.org/10.1530/EDM-18-0125

Hypercalcitoninaemia in pseudohypoparathyroidism type 1A and type 1B. / Yavropoulou, Maria P.; Chronopoulos, Efstathios; Trovas, George; Avramidis, Emmanouil; Elli, Francesca Marta; Mantovani, Giovanna; Zebekakis, Pantelis; Yovos, John G.

In: Endocrinology, Diabetes and Metabolism Case Reports, Vol. 2019, No. 1, 18-0125, 01.01.2019.

Research output: Contribution to journalArticle

Yavropoulou, MP, Chronopoulos, E, Trovas, G, Avramidis, E, Elli, FM, Mantovani, G, Zebekakis, P & Yovos, JG 2019, 'Hypercalcitoninaemia in pseudohypoparathyroidism type 1A and type 1B', Endocrinology, Diabetes and Metabolism Case Reports, vol. 2019, no. 1, 18-0125. https://doi.org/10.1530/EDM-18-0125
Yavropoulou, Maria P. ; Chronopoulos, Efstathios ; Trovas, George ; Avramidis, Emmanouil ; Elli, Francesca Marta ; Mantovani, Giovanna ; Zebekakis, Pantelis ; Yovos, John G. / Hypercalcitoninaemia in pseudohypoparathyroidism type 1A and type 1B. In: Endocrinology, Diabetes and Metabolism Case Reports. 2019 ; Vol. 2019, No. 1.
@article{95693f624f9f4201941ae985a22e44b4,
title = "Hypercalcitoninaemia in pseudohypoparathyroidism type 1A and type 1B",
abstract = "Pseudohypoparathyroidism (PHP) is a heterogeneous group of rare endocrine disorders characterised by normal renal function and renal resistance to the action of the parathyroid hormone. Type 1A (PHP1A), which is the most common variant, also include developmental and skeletal defects named as Albright hereditary osteodystrophy (AHO). We present two cases, a 54- and a 33-year-old male diagnosed with PHP who were referred to us for persistently high levels of serum calcitonin. AHO and multinodular goitre were present in the 54-year-old male, while the second patient was free of skeletal deformities and his thyroid gland was of normal size and without nodular appearance. We performed GNAS molecular analysis (methylation status and copy number analysis by MS-MLPA) in genomic DNA samples for both patients. The analysis revealed a novel missense variant c.131T>G p.(Leu44Pro) affecting GNAS exon 1, in the patient with the clinical diagnosis of PHP1A. This amino acid change appears to be in accordance with the clinical diagnosis of the patient. The genomic DNA analysis of the second patient revealed the presence of the recurrent 3-kb deletion affecting the imprinting control region localised in the STX16 region associated with the loss of methylation (LOM) at the GNAS A/B differentially methylated region and consistent with the diagnosis of an autosomal dominant form of PHP type 1B (PHP1B). In conclusion, hypercalcitoninaemia may be encountered in PHP1A and PHP1B even in the absence of thyroid pathology.",
author = "Yavropoulou, {Maria P.} and Efstathios Chronopoulos and George Trovas and Emmanouil Avramidis and Elli, {Francesca Marta} and Giovanna Mantovani and Pantelis Zebekakis and Yovos, {John G.}",
year = "2019",
month = "1",
day = "1",
doi = "10.1530/EDM-18-0125",
language = "English",
volume = "2019",
journal = "Endocrinology, Diabetes and Metabolism Case Reports",
issn = "2052-0573",
publisher = "BioScientifica Ltd.",
number = "1",

}

TY - JOUR

T1 - Hypercalcitoninaemia in pseudohypoparathyroidism type 1A and type 1B

AU - Yavropoulou, Maria P.

AU - Chronopoulos, Efstathios

AU - Trovas, George

AU - Avramidis, Emmanouil

AU - Elli, Francesca Marta

AU - Mantovani, Giovanna

AU - Zebekakis, Pantelis

AU - Yovos, John G.

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Pseudohypoparathyroidism (PHP) is a heterogeneous group of rare endocrine disorders characterised by normal renal function and renal resistance to the action of the parathyroid hormone. Type 1A (PHP1A), which is the most common variant, also include developmental and skeletal defects named as Albright hereditary osteodystrophy (AHO). We present two cases, a 54- and a 33-year-old male diagnosed with PHP who were referred to us for persistently high levels of serum calcitonin. AHO and multinodular goitre were present in the 54-year-old male, while the second patient was free of skeletal deformities and his thyroid gland was of normal size and without nodular appearance. We performed GNAS molecular analysis (methylation status and copy number analysis by MS-MLPA) in genomic DNA samples for both patients. The analysis revealed a novel missense variant c.131T>G p.(Leu44Pro) affecting GNAS exon 1, in the patient with the clinical diagnosis of PHP1A. This amino acid change appears to be in accordance with the clinical diagnosis of the patient. The genomic DNA analysis of the second patient revealed the presence of the recurrent 3-kb deletion affecting the imprinting control region localised in the STX16 region associated with the loss of methylation (LOM) at the GNAS A/B differentially methylated region and consistent with the diagnosis of an autosomal dominant form of PHP type 1B (PHP1B). In conclusion, hypercalcitoninaemia may be encountered in PHP1A and PHP1B even in the absence of thyroid pathology.

AB - Pseudohypoparathyroidism (PHP) is a heterogeneous group of rare endocrine disorders characterised by normal renal function and renal resistance to the action of the parathyroid hormone. Type 1A (PHP1A), which is the most common variant, also include developmental and skeletal defects named as Albright hereditary osteodystrophy (AHO). We present two cases, a 54- and a 33-year-old male diagnosed with PHP who were referred to us for persistently high levels of serum calcitonin. AHO and multinodular goitre were present in the 54-year-old male, while the second patient was free of skeletal deformities and his thyroid gland was of normal size and without nodular appearance. We performed GNAS molecular analysis (methylation status and copy number analysis by MS-MLPA) in genomic DNA samples for both patients. The analysis revealed a novel missense variant c.131T>G p.(Leu44Pro) affecting GNAS exon 1, in the patient with the clinical diagnosis of PHP1A. This amino acid change appears to be in accordance with the clinical diagnosis of the patient. The genomic DNA analysis of the second patient revealed the presence of the recurrent 3-kb deletion affecting the imprinting control region localised in the STX16 region associated with the loss of methylation (LOM) at the GNAS A/B differentially methylated region and consistent with the diagnosis of an autosomal dominant form of PHP type 1B (PHP1B). In conclusion, hypercalcitoninaemia may be encountered in PHP1A and PHP1B even in the absence of thyroid pathology.

UR - http://www.scopus.com/inward/record.url?scp=85067176698&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85067176698&partnerID=8YFLogxK

U2 - 10.1530/EDM-18-0125

DO - 10.1530/EDM-18-0125

M3 - Article

VL - 2019

JO - Endocrinology, Diabetes and Metabolism Case Reports

JF - Endocrinology, Diabetes and Metabolism Case Reports

SN - 2052-0573

IS - 1

M1 - 18-0125

ER -